First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4+bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC)
ANNALS OF ONCOLOGY（2006）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要